Filing Flows › Prothena Corp Public (PRTA) › R&D spending
Prothena Corp Public (PRTA) R&D spending by quarter
Prothena Corp Public's R&D spending was $8.4M in Q3 2026 (third quarter 2026), -4% from Q2 2026. Over the last 5 quarters it ranged from $8.4M (Q3 2026) to $50.8M (Q1 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $8.4M | -4% | -71% |
| Q2 2026 | $8.8M | -70% | -78% |
| Q3 2025 | $28.9M | -29% | — |
| Q2 2025 | $40.5M | -20% | — |
| Q1 2025 | $50.8M | — | — |
Q3 2026 at a glance
Prothena Corp Public, Q3 2026: revenue $620K (-74% year over year), net loss $16.5M, operating cash flow −$12.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Prothena Corp Public's R&D spending?
Prothena Corp Public's R&D spending was $8.4M in Q3 2026 (third quarter 2026), -4% from Q2 2026.
How has Prothena Corp Public's R&D spending changed?
Over the last 5 quarters it ranged from $8.4M (Q3 2026) to $50.8M (Q1 2025).